

CHAPTER ONE: INTRODUCTION	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THIS STUDY	1
INTENDED AUDIENCE.....	1
SCOPE OF REPORT	2
METHODOLOGY	2
INFORMATION SOURCES.....	3
AUTHOR’S CREDENTIALS	3
RELATED BCC REPORTS	3
BCC ONLINE SERVICES.....	3
DISCLAIMER	4
 CHAPTER TWO: SUMMARY.....	 5
SUMMARY.....	5
<i>SUMMARY TABLE THE WORLDWIDE MARKET FOR THERAPEUTIC VACCINES BY INDICATION, THROUGH 2014 (\$ MILLIONS)</i>	6
<i>SUMMARY FIGURE THE WORLDWIDE MARKET FOR THERAPEUTIC VACCINES BY INDICATION, 2010-2014</i>	6
 CHAPTER THREE: OVERVIEW	 7
DEFINITION OF A THERAPEUTIC VACCINE.....	7
IMMUNE SYSTEM OVERVIEW: CAST OF CHARACTERS	7
B-CELLS, T-CELLS AND ANTIGEN-PRESENTING CELLS.....	7
B-Cells.....	8
T-Cells.....	8
Antigen-Presenting Cells	8
CELLULAR VERSUS HUMORAL IMMUNITY.....	8
INNOVATIVE APPROACHES TO VACCINE TECHNOLOGY	9
DNA VACCINES.....	9
CARBOHYDRATE VACCINES.....	9
THE ROLE OF ADJUVANTS	10
ATTRACTIVE FEATURES OF THERAPEUTIC VACCINES VERSUS OTHER CLASSES OF THERAPIES.....	11
<i>TABLE 1 FEATURES OF THERAPEUTIC VACCINES VERSUS OTHER DRUG CLASSES</i>	11
THERAPEUTIC VACCINES APPROVED FOR CLINICAL USE OR IN CLINICAL TRIALS.....	11
<i>TABLE 2 THERAPEUTIC VACCINES IN CLINICAL TRIALS, ORDERED BY PHASE</i>	11
<i>TABLE 2 (CONTINUED)</i>	12
<i>TABLE 2 (CONTINUED)</i>	13
<i>TABLE 2 (CONTINUED)</i>	14
<i>TABLE 2 (CONTINUED)</i>	15
<i>TABLE 3 NUMBER OF THERAPEUTIC VACCINES IN CLINICAL TRIALS, BY PHASE</i>	15

<i>FIGURE 1 VACCINES IN CLINICAL TRIALS BY INDICATION, 2010</i> <i>(%)</i>	16
<i>TABLE 4 VACCINES IN CLINICAL TRIALS BY TECHNOLOGY</i>	16
<i>TABLE 5 COMPANIES WITH THERAPEUTIC VACCINES IN</i> <i>CLINICAL TRIALS</i>	17
CHAPTER FOUR: TECHNOLOGY OVERVIEW	18
TYPES OF THERAPEUTIC VACCINES	18
<i>TABLE 6 COMPARISON OF AUTOLOGOUS VERSUS ALLOGENEIC</i> <i>VACCINES</i>	18
<i>TABLE 7 NUMBER OF ALLOGENEIC AND AUTOLOGOUS</i> <i>THERAPEUTIC VACCINES IN DEVELOPMENT BY PHASE</i>	19
CHAPTER FIVE: PATENT EVALUATION.....	20
PATENT LENGTHS AND MARKET EXCLUSIVITY.....	20
<i>TABLE 8 PATENT EXPIRATION DATES FOR THERAPEUTIC</i> <i>VACCINES IN LATE STAGES OF DEVELOPMENT</i>	21
CHAPTER SIX: PRODUCTS	22
ADDICTION VACCINES	22
<i>TABLE 9 ADDICTION VACCINES IN DEVELOPMENT BY PHASE</i>	23
<i>TABLE 10 THE WORLDWIDE MARKET FOR ADDICTION VACCINES,</i> <i>THROUGH 2014 (\$ MILLIONS)</i>	23
COCAINE ADDICTION VACCINES	24
The Market for Cocaine Addiction Vaccines	24
TA-CD	25
NICOTINE ADDICTION VACCINES	26
The Market for Nicotine Addiction Vaccines.....	27
NicVAX.....	28
<i>TABLE 11 NICOTINE ABSTINENCE RATE AT 12 MONTHS IN</i> <i>DIFFERENT STUDIES (%)</i>	29
NIC002	29
TA-NIC	30
AUTOIMMUNE DISEASE VACCINES	31
<i>TABLE 12 AUTOIMMUNE DISEASE VACCINES IN DEVELOPMENT</i> <i>BY PHASE</i>	31
DIABETES (TYPE 1)	31
Diamyd (rhGAD65).....	32
Diamyd (rhGAD65) (Continued)	33
BHT-3021	34
Tovaxin.....	35
TNFaKinoid	35
CANCER VACCINES	36
CANCER STATISTICS.....	37
U.S. Cancer Statistics.....	37

<i>TABLE 13 INCIDENCE, MORTALITY, AND SURVIVAL RATES FOR COMMON CANCERS IN THE U.S., 2009</i>	38
<i>TABLE 14 CANCER PREVALENCE RATES IN THE U.S., 2006 (THOUSANDS)</i>	39
Current Treatment Methods.....	39
Surgery	39
Radiation Therapy	40
Pharmaceutical Therapy	40
CANCER VACCINES: A NEW MODALITY OF CARE	41
The Primary Therapeutic Role for Cancer Vaccines.....	42
The Immune System and Cancer.....	43
Antigens: Their Role in Cancer Vaccines	43
Antigens Used in Cancer Vaccine Development	44
Carcinoembryonic Antigen.....	44
Ganglioside Molecules	44
Heat Shock Proteins	45
MART-1.....	45
Prostate-Specific Antigen	45
Sialyl Tn.....	46
Tyrosinase.....	46
MAGE.....	46
NY-ESO-1	46
MUC1	46
Vaccine Development: Strategies.....	47
Vaccine Development: ... (Continued)	48
A Summary of Two Approaches: Low-technology vs. High- technology.....	49
Vaccine Types	49
Antigen/Adjuvant Vaccines	49
Dendritic Cell Vaccines (DCs)	49
DNA and Viral Vector Vaccines	49
Idiotypic Vaccines	50
Oncolytic Virus Vaccines	50
Whole Cell Tumor Vaccines.....	50
<i>TABLE 15 TYPES OF VACCINES IN DEVELOPMENT FOR CANCER TREATMENT</i>	51
The Long Road to Market.....	51
The Market for Cancer Vaccines.....	52
<i>TABLE 16 ESTIMATED INITIAL U.S. MARKET OPPORTUNITY FOR CANCER VACCINES BY INDICATION</i>	52
<i>TABLE 17 WORLDWIDE MARKET FOR HUMAN CANCER VACCINES BY TYPE, THROUGH 2014 (\$ MILLIONS)</i>	53

<i>TABLE 18 THE MARKET FOR HUMAN CANCER VACCINES, BY TECHNOLOGY (AUTOLOGOUS VERSUS ALLOGENEIC), WORLDWIDE, THROUGH 2014 (\$ MILLIONS)</i>	53
<i>FIGURE 2 NUMBER OF AUTOLOGOUS VERSUS ALLOGENEIC CANCER VACCINES IN DEVELOPMENT, 2010 (%)</i>	54
<i>TABLE 19 THE WORLDWIDE MARKET FOR HUMAN CANCER VACCINES, BY INDICATION, THROUGH 2014 (\$ MILLIONS)</i>	54
CANCER VACCINES IN DEVELOPMENT.....	55
<i>TABLE 20 CANCER VACCINES IN PHASE II OR LATER TRIALS BY PHASE</i>	55
<i>TABLE 20 (CONTINUED)</i>	56
CANCER VACCINES APPROVED FOR USE ON THE WORLDWIDE MARKET.....	57
Melacine.....	57
Oncophage.....	58
Oncophage (Continued)	59
M-Vax.....	60
M-Vax (Continued).....	61
CANCER VACCINES IN DEVELOPMENT.....	62
Provenge (APC8015, Sipuleucel-T)	62
<i>TABLE 21 PROVENGE PHASE III CLINICAL TRIAL RESULTS</i>	63
Provenge (Continued)	64
OncoVAX.....	65
OncoVAX (Continued).....	66
MyVax	67
BiovaxId	68
BiovaxId (Continued).....	69
Multikine.....	70
Multikine (Continued)	71
GSK1572932A.....	72
<i>TABLE 22 EXPRESSION OF MAGE-A3 ANTIGEN BY TUMOR TYPE (%)</i>	73
GSK2132231A.....	74
BLP25 Liposome Vaccine (Stimuvax).....	74
BLP25 Liposome ... (Continued).....	75
BLP25 Liposome ... (Continued).....	76
TroVax.....	77
PR1 Peptide Vaccine.....	78
Allovectin-7	78
Allovectin-7 (Continued).....	79
Belagenpumatucel-L (Lucanix).....	80
GV1001.....	80
CB-10-01	81
MelCancerVac.....	81

GRNVAC1	82
DCVax-Brain	83
AGS-003	84
Glionix	84
CYT004-MelQbG10.....	85
CDX-110 (PF-04948568).....	85
GI-4000.....	86

TABLE 23 OCCURRENCE OF RAS MUTATIONS IN VARIOUS SOLID TUMORS (%).....

HyperAcute-Pancreas.....	86
HyperAcute Melanoma.....	87
HyperAcute-Lung	87
PEP223.....	88
IMA901.....	88
JX-594	89
Onyvax-P (ONY-P1).....	89
Onyvax-P (ONY-P1) (Continued)	90
TG4010 (MVA-MUC1-IL2).....	91
TG1042 (Ad-IFN γ)	92
TG4001/R3484 (MVA-HPV-IL2)	92
Abagovomab.....	93
CV9103.....	93
AE37.....	94
NeuVax (E75).....	95
ProstVac	95
INFECTIOUS DISEASE VACCINES.....	96

TABLE 24 INFECTIOUS DISEASE VACCINES IN DEVELOPMENT BY PHASE.....

HIV/AIDS.....	97
THE HIV INFECTION PROCESS.....	97
HIV TRANSMISSION	98
CONFUSION REGARDING THE PROPHYLACTIC VERSUS THERAPEUTIC ACTIVITY OF AIDS VACCINES	98
BARRIERS TO DEVELOPING AND TESTING AIDS VACCINES.....	99
Barriers to Developing ...(Continued)	100
WHAT HAS BEEN LEARNED	101
THE MARKET FOR AIDS VACCINES	102
HIV THERAPEUTIC VACCINES IN DEVELOPMENT	102
Results of Early Trials of HIV/AIDS Vaccines	103
AIDSVAX, the Most Advanced HIV Vaccine Candidate but with Mixed Results	104
The Failure of Merck's V520 Prophylactic and Therapeutic Vaccine.....	105

The Remune (AG1661, HIV-1 Immunogen) Saga	105
The Remune ... (Continued).....	106
ALVAC-HIV (vCP1521), AIDSVAX Combination.....	107
HIV Vaccine 732461	108
Prophylactic and/or Therapeutic HIV Vaccine.....	108
Vacc-4x	108
DermaVir (LC002)	109
AGS-004	109
OTHER INFECTIOUS DISEASE VACCINES (OUTSIDE HIV)	110
HEPATITIS C.....	110
GI-5005.....	111
TG4040 (MVA-HCV).....	111
IC41	112
NEUROLOGICAL DISEASE VACCINES.....	112
<i>TABLE 25 NEUROLOGICAL DISEASE VACCINES IN DEVELOPMENT</i>	112
THE MARKET FOR NEUROLOGICAL DISEASE VACCINES	113
Alzheimer's Disease Vaccine (AN-1792) (Discontinued).....	113
ACC-001	114
CAD106	114
PARKINSON'S DISEASE VACCINE	115
OTHER DISEASE VACCINES	115
<i>TABLE 26 OTHER DISEASE VACCINES IN DEVELOPMENT</i>	115
CYT006-AngQb	115
Angiotensin Therapeutic Vaccine	116
Angiotensin ... (Continued).....	117
CHAPTER SEVEN: MAJOR COMPANIES AND MARKET SHARE.....	118
MARKET SHARE	118
<i>TABLE 27 FORECASTED SALES AND MARKET SHARE OF</i> <i>COMPANIES INVOLVED IN THERAPEUTIC VACCINES, 2014 (\$</i> <i>MILLIONS/%)</i>	118
COMPANY PROFILES	119
AFFIRIS.....	119
ANTIGENICS.....	120
ARGOS THERAPEUTICS	121
BAVARIAN NORDIC.....	121
BIOVEST INTERNATIONAL	122
CELLDEX THERAPEUTICS	123
CEL-SCI.....	123
CELTIC PHARMA	124
CUREVAC	124
CYTOS BIOTECHNOLOGY.....	125
DENDREON.....	126
DIAMYD MEDICAL	127
ELAN	127

GENEXINE	128
GERON	128
GLAXOSMITHKLINE	129
GLAXOSMITHKLINE – U.S.	129
GLOBEIMMUNE	130
KAEL	131
MERCK KGAA (MERCK SERONO)	131
NABI BIOPHARMACEUTICALS	132
NEWLINK GENETICS.....	132
NOVARTIS	133
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH	133
NOVARX.....	133
ONCOTHYREON.....	134
OXFORD BIOMEDICA.....	134
PFIZER	135
TRANSGENE	136
VACCINOGEN.....	137
VACCINOGEN – U.S.....	137
VICAL	137
Vical (Continued).....	138

CHAPTER EIGHT: INTERNATIONAL ASPECTS AND REGULATORY ISSUES	139
MARKET BY REGION	139
<i>TABLE 28 GLOBAL FORECAST FOR THERAPEUTIC VACCINES</i>	
<i>MARKET BY REGION, THROUGH 2014 (\$ MILLIONS)</i>	139
MARKET BY REGION (CONTINUED).....	140
UNITED STATES	141
The FDA Modernization Act of 1997	141
Fast-track Status.....	141
Special Protocol Assessments	142
New Surveillance and Safety Requirements.....	142
Approvable Letters No More.....	143
Medicare.....	143
Other Healthcare Changes.....	144
EUROPEAN UNION	144
New Drug Approvals and Innovation	144
New Drug ... (Continued)	145
Drug Reimbursement and Reference Pricing.....	146
Relocation of R&D	147
Regulatory Climate.....	147
JAPAN	148
New Drug Approvals	148
Regulatory Climate.....	148
Relationship between Academia and Industry	149

CHAPTER NINE: FUTURE DIRECTIONS.....	150
THERAPEUTIC VACCINES AS FIRST-LINE THERAPIES	150
THE ROLE OF BIOMARKERS	151
VACCINES AND CLINICAL TRIAL DESIGN	151
COMBINATION THERAPIES.....	152